Literature DB >> 12019090

Precision and accuracy of fluconazole susceptibility testing by broth microdilution, Etest, and disk diffusion methods.

A L Barry1, M A Pfaller, R P Rennie, P C Fuchs, S D Brown.   

Abstract

Interpretive agreements among the results of fluconazole broth microdilution tests, Etests, and disk diffusion tests were documented by evaluating 495 Candida spp. Microdilution reference test results were in agreement with 96% of the Etest results; most discrepancies were minor differences. Fluconazole resistance of Candida krusei strains often required a full 48 h of incubation in order to be observed by the standard method. For the disk diffusion tests that were performed on Mueller-Hinton agar with glucose and methylene blue, 97% of results were in agreement with those of the reference test, especially when zones of inhibition were measured after the first 24 h of incubation. Some Candida glabrata isolates failed to grow satisfactorily until a full 48 h of incubation was completed. Precision was determined by testing 50 selected isolates in triplicate in each of three laboratories. The reproducibility of results of disk diffusion tests was comparable to that of the reference method. With all procedures, determination of test results was particularly challenging with some strains, and new methods are needed in order to improve endpoint definition.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12019090      PMCID: PMC127270          DOI: 10.1128/AAC.46.6.1781-1784.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  When should Candida isolates be tested for susceptibility to azole antifungal agents?

Authors:  J Bille
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

Review 3.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

4.  In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus.

Authors:  H C Korting; M Ollert; A Georgii; M Fröschl
Journal:  J Clin Microbiol       Date:  1988-12       Impact factor: 5.948

5.  Multicenter evaluation of four methods of yeast inoculum preparation.

Authors:  M A Pfaller; L Burmeister; M S Bartlett; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1988-08       Impact factor: 5.948

6.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

7.  Fluconazole disk diffusion procedure for determining susceptibility of Candida species.

Authors:  A L Barry; S D Brown
Journal:  J Clin Microbiol       Date:  1996-09       Impact factor: 5.948

8.  Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose.

Authors:  A Espinel-Ingroff; M Pfaller; M E Erwin; R N Jones
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

9.  Development of resistance in candida isolates from patients receiving prolonged antifungal therapy.

Authors:  P Fan-Havard; D Capano; S M Smith; A Mangia; R H Eng
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Comparison of broth macrodilution, broth microdilution, and E test antifungal susceptibility tests for fluconazole.

Authors:  D L Sewell; M A Pfaller; A L Barry
Journal:  J Clin Microbiol       Date:  1994-09       Impact factor: 5.948

  10 in total
  38 in total

1.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

2.  Evaluation of the Etest and disk diffusion methods for determining susceptibilities of 235 bloodstream isolates of Candida glabrata to fluconazole and voriconazole.

Authors:  M A Pfaller; D J Diekema; L Boyken; S A Messer; S Tendolkar; R J Hollis
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

3.  In vitro susceptibility of a large collection of Candida Strains against fluconazole and voriconazole by using the CLSI disk diffusion assay.

Authors:  Ana Carolina Azevedo; Fernando César Bizerra; Daniel Arquimedes da Matta; Leila Paula de Almeida; Robert Rosas; Arnaldo Lopes Colombo
Journal:  Mycopathologia       Date:  2010-12-23       Impact factor: 2.574

Review 4.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program.

Authors:  M A Pfaller; L Boyken; S A Messer; S Tendolkar; R J Hollis; D J Diekema
Journal:  J Clin Microbiol       Date:  2005-10       Impact factor: 5.948

7.  Audit of laboratory mycology services for the management of patients with fungal infections in the northwest of England.

Authors:  I A Hassan; P Critten; B Isalska; D W Denning
Journal:  J Clin Pathol       Date:  2006-07       Impact factor: 3.411

8.  Caspofungin Etest endpoint for Aspergillus isolates shows poor agreement with the reference minimum effective concentration.

Authors:  Jeff Fuller; Adam Schofield; Safeer Jiwa; Crystal Sand; Brad Jansen; Robert Rennie
Journal:  J Clin Microbiol       Date:  2009-12-09       Impact factor: 5.948

9.  Quality control limits for fluconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.

Authors:  A Barry; J Bille; S Brown; D Ellis; J Meis; M Pfaller; R Rennie; M Rinaldi; T Rogers; M Traczewski
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

10.  Quality control limits for voriconazole disk susceptibility tests on Mueller-Hinton agar with glucose and methylene blue.

Authors:  M A Pfaller; A Barry; J Bille; S Brown; D Ellis; J F Meis; R Rennie; M Rinaldi; T Rogers; M Traczewski
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.